Biologics Market – Monoclonal Antibodies, Therapeutic Proteins And Vaccines

Press Release

The Business Research Company’s “Biologics Market By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By Trends, By Regions And By Key Players – Global Forecast To 2021” under pharmaceutical category covers market characteristics, key players, market size and trends from 2019 to 2022

The biologics industry comprises companies manufacturing biological products. Biological products include a wide range of products such as vaccines, allergenics, somatic cells, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies. Specifically, most biologic medicines are developed using recombinant DNA (rDNA) technology.

View complete Report:

The Biologics Market Segmentation

By Type – The biologics market can be segmented by type into

  1. a) Monoclonal Antibodies (mAbs)
  2. b) Therapeutic Proteins
  3. c) Vaccines

Vaccines had the highest growth rate of nearly 5.86% during the historic period. The fastest growth in the historic period can be attributed to the increasing government and non-government initiatives for vaccine R&D activities and prevention of various infectious diseases. Various bivalent and pentavalent vaccines that can prevent an individual from more than one disease have also been developed and are being administered in many countries across the world.

Major trends influencing the biologics market include:

Demand For Biologics In The Treatment Of Complex Diseases – Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease that have limited treatment options. There has been a significant advance in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab (Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.

Development And Increasing Demand For Next Generation Biologics – Antibody drug conjugates (ADCs) are being used to treat diseases such as inflammatory, oncology and respiratory diseases. ADCs are monoclonal antibodies that have the ability to discriminate between healthy and diseased tissues and kill the diseased tissues when detected. ADCs are also being used in cancer treatment by attaching them to cancer-killing drugs that kill cancerous cells, leaving healthy tissues unaffected.

Request A Sample Report At:

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]

Follow us on LinkedIn:

This post was originally published on Analytics News